This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008;5(1):25-36.

doi: 10.1016/j.ddstr.2008.05.006.

Cyclooxygenase products and atherosclerosis

Macrae F Linton¹, Sergio Fazio

Affiliations

PMID: 19343100
PMCID: PMC2630286
DOI: 10.1016/j.ddstr.2008.05.006

Cyclooxygenase products and atherosclerosis

Macrae F Linton et al. Drug Discov Today Ther Strateg. 2008.

. 2008;5(1):25-36.

doi: 10.1016/j.ddstr.2008.05.006.

Authors

Macrae F Linton¹, Sergio Fazio

Affiliation

¹ Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

PMID: 19343100
PMCID: PMC2630286
DOI: 10.1016/j.ddstr.2008.05.006

No abstract available

PubMed Disclaimer

Figures

Figure 1
Arachidonic acid (AA) is first oxidized by cyclooxygenase (COX)-1 or COX-2 to PGG2, which is then peroxidized to PGH2, an unstable endoperoxide that serves as the common precursor for the 5 principle prostaglandins. Synthesis of Thromboxane(TX) A2, PGI2, PGE2, PGD2, and PGF2a is mediated by specific synthases (TXAS, PGIS, PGES, PGDS, and PGFS). * Three synthases have been identified for PGE2: cPGES, mPGES-1, and mPGES-2; two synthases generate PGD2. Prostaglandins mediate their biological effects by activating the indicated cell surface G-protein-coupled receptors[111].

Figure 2
Proposed roles for prostaglandins in atherothrombosis according to cell type.

See this image and copyright information in PMC

Similar articles

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Belton O, et al. Circulation. 2000 Aug 22;102(8):840-5. doi: 10.1161/01.cir.102.8.840. Circulation. 2000. PMID: 10952950 Clinical Trial.
Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.
Mitchell JA, Shala F, Pires MEL, Loy RY, Ravendren A, Benson J, Urquhart P, Nicolaou A, Herschman HR, Kirkby NS. Mitchell JA, et al. Sci Adv. 2021 Mar 19;7(12):eabf6054. doi: 10.1126/sciadv.abf6054. Print 2021 Mar. Sci Adv. 2021. PMID: 33741600 Free PMC article.
Cyclooxygenase-2 and atherosclerosis.
Linton MF, Fazio S. Linton MF, et al. Curr Opin Lipidol. 2002 Oct;13(5):497-504. doi: 10.1097/00041433-200210000-00005. Curr Opin Lipidol. 2002. PMID: 12352013 Review.
Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Belton OA, et al. Circulation. 2003 Dec 16;108(24):3017-23. doi: 10.1161/01.CIR.0000104565.78013.AD. Epub 2003 Nov 24. Circulation. 2003. PMID: 14638539
Cyclooxygenase inhibition and atherothrombosis.
Sohn HY, Krötz F. Sohn HY, et al. Curr Drug Targets. 2006 Oct;7(10):1275-84. doi: 10.2174/138945006778559102. Curr Drug Targets. 2006. PMID: 17073588 Review.

See all similar articles

Cited by

The Perspectives of Platelet Proteomics in Health and Disease.
Chaudhary PK, Upadhayaya S, Kim S, Kim S. Chaudhary PK, et al. Biomedicines. 2024 Mar 6;12(3):585. doi: 10.3390/biomedicines12030585. Biomedicines. 2024. PMID: 38540198 Free PMC article. Review.
Influence of variability in the cyclooxygenase pathway on cardiovascular outcomes of nephrosclerosis patients.
González LM, Robles NR, Mota-Zamorano S, Valdivielso JM, González-Rodríguez L, López-Gómez J, Gervasini G. González LM, et al. Sci Rep. 2023 Jan 23;13(1):1253. doi: 10.1038/s41598-022-27343-z. Sci Rep. 2023. PMID: 36690661 Free PMC article.
Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life.
Kelishadi R. Kelishadi R. Open Cardiovasc Med J. 2010;4:24-9. doi: 10.2174/1874192401004020024. Epub 2010 Feb 23. Open Cardiovasc Med J. 2010. PMID: 21804638 Free PMC article.
Lipid metabolism patterns and relevant clinical and molecular features of coronary artery disease patients: an integrated bioinformatic analysis.
Liao Y, Dong Z, Liao H, Chen Y, Hu L, Yu Z, Xia Y, Zhao Y, Fan K, Ding J, Yao X, Deng T, Yang R. Liao Y, et al. Lipids Health Dis. 2022 Sep 10;21(1):87. doi: 10.1186/s12944-022-01696-w. Lipids Health Dis. 2022. PMID: 36088434 Free PMC article.
Inflammatory Mediators in Xanthelasma Palpebrarum: Histopathologic and Immunohistochemical Study.
Govorkova MS, Milman T, Ying GS, Pan W, Silkiss RZ. Govorkova MS, et al. Ophthalmic Plast Reconstr Surg. 2018 May/Jun;34(3):225-230. doi: 10.1097/IOP.0000000000000921. Ophthalmic Plast Reconstr Surg. 2018. PMID: 28481769 Free PMC article.

See all "Cited by" articles

References

1. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta. 1991;1083:1–17. - PubMed
1. DuBois RN, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073. - PubMed
1. Raz A, et al. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. Journal of Biological Chemistry. 1988;263(6):3022–3028. - PubMed
1. Reed DW, et al. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins. 1996;52(4):269–284. - PubMed
1. Wu KK. Cyclooxygenase-2 induction in congestive heart failure friend or foe? Circulation. 1998;98:95–96. - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central